Eye on the Cure Podcast | Episode 104: Emerging XLRP gene therapy shows promising clinical trial results
Eye on the Cure
Dr. Daniel Chung explains what laru-zova is, how it works and next steps as Beacon works to earn FDA approval for the potential gene therapy.
October 21, 2026. Host Maddie Mossman talks with Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, about Laru-zova, an emerging treatment for X-linked retinitis pigmentosa. Based on encouraging clinical trial results, Beacon plans to begin a rolling FDA submission for the potential gene therapy later this year. The Foundation funded pre-clinical research that went on to became laru-zova.
